source
- Novo to pay Hengrui up to $2.6 billion for rights to weekly obesity pill HRS-1596Novo announced a deal with China-based Hengrui Pharma, paying $300 million up front for rights to HRS-1596, a once‑weekly obesity pill. The agreement could rise to $2.6 billion if the candidate me…
- Anthropic joins ARPA‑H clinical AI moonshot and will host a closed‑door health‑care eventAnthropic, an artificial‑intelligence firm, announced it is joining a new clinical‑AI initiative launched by the U.S. Biomedical Advanced Research Projects Agency‑Health (ARPA‑H). The partnership…